exendin-4 (purple, 1 g/kg body weight) or vehicle (black) injection on cumulative ad libitum food intake in 12- to 18-week-old male WT ( K ) and Bbs5 / ( L ) mice over 24 hours ( n = 8 per group)
Eligible Diagnoses We are reviewing cases involving documented diagnoses of: Gastroparesis , stomach paralysis, or gastric stasis Ileus or intestinal obstruction , including bowel blockage Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) , sudden vision loss Your medical records must confirm that you received medical treatment or were hospitalized for one of the above conditions
It is very likely to cause heartburn and nausea
A larger phase III trial involving hundreds or thousands of patients would be ideal to confirm these benefits
However, while using semaglutide, it was found that some patients were also losing weight, leading to it being licensed for weight loss in the UK for non-diabetics (Wegovy)
This isnt just about fitting into smaller clothes